Aridis Pharmaceuticals has filed for a $34.5 million IPO and plans to plans to list on the Nasdaq using the symbol ‘ARDS.’ The company will move its fully human antibodies for hospital-related infections like HAP/VAP into late-phase clinical trials.
The San Jose, California-based company plans to list on the Nasdaq using the symbol ARDS. Pricing terms were not disclosed. Founded in 2003, Aridis acquired six anti-infective immunotherapies and its discovery platform from Switzerland-based Kenta Biotech in 2013.
Its lead candidate, AR-301, is being developed as an add-on to standard-of-care antibiotic treatments for hospital-acquired or ventilator-associated pneumonia infections, or HAP/VAP, caused by the Staphylococcus aureus bacteria, including MRSA strains.